Pushing the boundaries of
innovation in oncology.

Loading...

Pushing the boundaries of
innovation in oncology.

Loading...

About

There is more innovation in cancer research today than ever before. Many of these efforts are disjointed and silo-ed and as a result often do not reach their full potential. If we can capture that potential, there is great opportunity for cancer patients.

Cullinan uniquely applies open innovation to the development of scientific oncology assets. Our approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, we seek to develop first-in-class or best-in-class assets that have the potential to significantly improve the lives of those living with cancer.

Drug development through
the prism of modern-day
portfolio management.

Our Approach

Cullinan was formed to advance a growing portfolio of innovative, early-stage assets by capitalizing on the latest scientific breakthroughs. The company is structured as a unique hybrid model that brings together certain aspects of an investment firm with a true operating company. As a result, we think about capital allocation and risk as much as we think about in-vivo results or clinical trial design.

  • Access to the world’s earliest stage oncology research through relationships with MPM Capital, academia, and pharma
  • Portfolio diversification across platforms, mechanisms and modalities
  • Led by a team of veteran oncology researchers, biopharma executives, and experienced entrepreneurs
Cullinan Development Engine

Team

At the core of any great company is its people. The Cullinan team is a group of accomplished professionals that share a vision for eradicating cancer.

Patrick Baeuerle, Ph.D.
Patrick Baeuerle, Ph.D.Co-Founder, Chief Scientific Officer, Biologics
Myles Clancy
Myles ClancyDirector, Clinical Operations
Parissa Daneshmand
Parissa DaneshmandSenior Associate, Finance
Owen Hughes
Owen HughesChief Executive Officer
Kristen Laguerre
Kristen LaguerreChief Financial Officer
Bochong Li, Ph.D., J.D.
Bochong Li, Ph.D., J.D.Director, Scientific Evaluation and IP
Naveen Mehta
Naveen MehtaAssociate Director, Preclinical R&D
Jennifer Michaelson, Ph.D.
Jennifer Michaelson, Ph.D.Vice President, Preclinical Research and Development
Briggs Morrison, M.D.
Briggs Morrison, M.D.Clinical Advisor
Asher Page, Ph.D.
Asher Page, Ph.D.Director, Business Development and Licensing
Erica Player
Erica PlayerExecutive Assistant and Office Supervisor
Corinne Savill, Ph.D.
Corinne Savill, Ph.D.Chief Business Officer
Greg Sieczkiewicz, J.D., Ph.D.
Greg Sieczkiewicz, J.D., Ph.D.Chief IP Counsel
David Witter, Ph.D.
David Witter, Ph.D.Vice President, Preclinical Research
Leigh Zawel, Ph.D.
Leigh Zawel, Ph.D.Chief Scientific Officer, Small Molecules

Board of Directors

Thomas Ebeling
Thomas Ebeling
Ansbert Gadicke, M.D.
Ansbert Gadicke, M.D.
Owen Hughes
Owen HughesChief Executive Officer
Morana Jovan-Embiricos, Ph.D.
Morana Jovan-Embiricos, Ph.D.
Tony Rosenberg
Tony Rosenberg

Investors